Clinical Trials · NCT02235987
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Aspireo Pharmaceuticals Limited
- Enrollment
- 20
- Start date
- Oct 2012
- Locations
- See registry
- Primary endpoint
- Participants With Trough Human Growth Hormone < 2.5 ug/mL